Almirall, S.A. has acquired products from Allergan’s Dermatology unit in the U.S. for a cash consideration of $550M. The products include Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid) and Cordran Tape (flurandrenolide), as well as sarecycline, a New Chemical Entity (NCE) currently under FDA review for the treatment of acne. These products expand Almirall’s presence in the U.S. through their subsidiary Aqua Pharmaceuticals, a manufacturer of established therapies for a range of dermatology indications including acne, eczema, dermatitis, actinic keratoses and bacterial infections.

“With this acquisition, Almirall is cementing its commitment to be a leader in medical dermatology, providing proven brands and innovative new therapies across a broad array of indications as a partner to our customers and patients,” said Ron Menezes, president and general manager, Aqua Pharmaceuticals. “The mature products complement our existing portfolio while sarecycline could soon become one of the promising new oral therapies, which exemplifies our renewed focus on innovation.” Should regulatory approvals be granted, Aqua will launch and market the approved product, which has been studied in patients with acne.

This agreement also includes a possible earn-out, as much as $100 million payable in 1Q22, pending business performance.